Checkpoint Capital L.P.
SAN FRANCISCO, CA · Quarter end: Sep 30, 2026 · Filed with SEC: Nov 13, 2026 · Open the SEC source ↗
Portfolio Return (1Y)——
Portfolio Value (AUM)Total value of the fund's US stock portfolio reported to the SEC.$442.3M2026 Q3
Positions8
Top-10 ConcentrationPercent of the portfolio in the 10 largest holdings. High means the fund is concentrated in few stocks.100.0%
What Changed This Quarter?
Top Holdings
ARGX
Argenx
39.3%
RYTM
Rhythm Pharmaceuticals
26.2%
RVMD
Revolution Medicines
19.6%
CYTK
Cytokinetics
7.7%
IRON
Disc Medicine
5.9%
SEPN
Septerna
0.6%
TRVI
Trevi Therapeutics
0.4%
OCS
Oculis
0.2%
New / Increased
2 new · 6 increased
SEPNNEW
Septerna
0.6%
OCSNEW
Oculis
0.2%
ARGX
Argenx
39.3%
+38.3%
IRON
Disc Medicine
5.9%
+66.5%
RYTM
Rhythm Pharmaceuticals
26.2%
+2.6%
CYTK
Cytokinetics
7.7%
+8.9%
RVMD
Revolution Medicines
19.6%
+3.1%
Reduced / Exited
0 reduced · 0 sold out
Read the 2026-Q2 quarterly report · 13F Filing Calendar
13F data shows quarter-end positions, is delayed by up to 45 days and covers only long positions in US-listed securities; short positions, most derivatives and non-US assets are not reported.